Plomestane Explained

Plomestane (; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer.^{[1] [2] [3] [4] [5]} It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.^[6]

In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.

See also

• Minamestane

Notes and References

1. Book: Macdonald F . Dictionary of Pharmacological Agents . 19 May 2012 . 1997 . CRC Press . 978-0-412-46630-4 . 1635.
2. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms . 20 May 2012 . 1999 . Springer . 978-0-7514-0499-9 . 227.
3. Lombardi P . The irreversible inhibition of aromatase (oestrogen synthetase) by steroidal compounds . Current Pharmaceutical Design . 1 . 23–50 (45) . 20 May 2012 . June 1995 . Bentham Science Publishers . 10.2174/1381612801666220524190226 . 249298105 .
4. Book: Kreider RB, Leutholtz BC, Katch FI, Katch VL . Exercise and Sport Nutrition . 20 May 2012 . 2009 . Exercise & Sport Nutrition . 978-0-9742965-6-2 . 350.
5. Kelloff GJ, Lubet RA, Lieberman R, etal . Aromatase inhibitors as potential cancer chemopreventives . Cancer Epidemiology, Biomarkers & Prevention . 7 . 1 . 65–78 . January 1998 . 9456245 .
6. Book: Avendaño C, Menéndez JC . Medicinal Chemistry of Anticancer Drugs . 20 May 2012 . 4 June 2008 . Elsevier . 978-0-444-52824-7 . 69.